CSIMarket Company Name, Ticker, Suppliers, else..
 
Lexeo Therapeutics Inc   (NASDAQ: LXEO)
 
Price: $4.2500 $0.00 0.000%
Day's High: $4.349999904632568 Week Perf: -10.71 %
Day's Low: $ 4.18 30 Day Perf: -14.31 %
Volume (M): 1,042,149 52 Wk High: $ 10.99
Volume (M$): $ 0 52 Wk Avg: $6.67
Open: $4.31 52 Wk Low: $3.99



 Market Capitalization (Millions $) 364
 Shares Outstanding (Millions) 86
 Employees 59
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -87
 Cash Flow (TTM) (Millions $) 36
 Capital Exp. (TTM) (Millions $) 0

Business Description


Lexeo Therapeutics Inc. is a biotechnology company that focuses on the development and commercialization of potentially transformative gene therapy products for the treatment of severe genetic disorders. The company aims to deliver these therapies using its proprietary adeno-associated viral (AAV) vector platform, which allows for the targeted and efficient delivery of genetic material to specific cells in the body. Lexeo Therapeutics is dedicated to advancing the field of gene therapy and improving the lives of patients with genetic diseases.


   Company Address: 345 Park Avenue South New York 10010 NY
   Company Phone Number: 547-9879   Stock Exchange / Ticker: NASDAQ LXEO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN   -13.21%    
BCRX   -18.07%    
EXEL   -4.59%    
GILD   -3.88%    
HALO   -1.78%    
NVAX   -7.19%    
• View Complete Report
   



Clinical Study

Advancements in Gene Therapy Lexeo Therapeutics Reports Promising Interim Data for LX2006 in Friedreich Ataxia Cardio...

Published Mon, Apr 7 2025 11:08 AM UTC

: Lexeo Therapeutics, a clinical-stage genetic medicine company, has announced positive interim results from its Phase 1/2 clinical trial for LX2006, a gene therapy targeting Friedreich ataxia (FA) cardiomyopathy. The interim data supports the advancement of LX2006 to a registrational study, and the company has planned a webcast to share further details. Friedreich ataxia...
Stocks on the Move

Promising Interim Clinical Trial Results Boost Confidence in Lexeo Therapeutics Gene Therapy Potential

Published Fri, Jul 19 2024 7:51 PM UTC

In the world of pharmaceutical sciences, the performance of biotech companies and the impact of clinical trial results play a crucial role in shaping investor sentiment. This article focuses on Lexeo Therapeutics Inc and explores the recent market performance of its shares, while analyzing the events surrounding the release of promising interim clinical trial results for the...
Clinical Study

Lexeo Therapeutics Makes Striking Progress in Gene Therapy for Cardiomyopathies, Paving the Way for Hope and Breakthr...

Published Mon, Jul 15 2024 10:00 AM UTC

Lexeo Therapeutics Revolutionizes the Treatment of Cardiomyopathies with Promising Clinical Data and Regulatory MilestonesLexeo Therapeutics, a leading gene therapy company, made significant strides in the development of innovative treatments for cardiomyopathies. The company recently announced positive interim Phase 1/2 clinical data of LX2006 for the Treatment of Friedreic...
Clinical Study

Lexeo Therapeutics to Reveal Interim Clinical Data of LX2006 for Friedreich Ataxia Cardiomyopathy in Investor Webcast...

Published Thu, Jul 11 2024 12:00 PM UTC

Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia CardiomyopathyLexeo Therapeutics, a clinical stage genetic medicine company focused on genetically defined cardiovascular diseases and APOE4-associated Alzheimer s disease, has recently revealed its plans to conduct an investor webcast to ...
Clinical Study

Lexeo Therapeutics Embarks on Accelerated Pathway for LX2006 Development for Friedreich Ataxia Cardiomyopathy by the Acquisition of Significant License Agreement

Published Mon, Apr 22 2024 11:30 AM UTC

Lexeo Therapeutics, a leading name in genetic medicine, has recently announced an arrangement empowering them to fast-track the development of their novel treatment for a rare disorder, Friedreich Ataxia Cardiomyopathy (FAC). The company has secured the rights to intellectual property, inclusive of pivotal trial data, from Weill Cornell Medicine, in relation to gene therapy ...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 1.55
PEG (TTM) -

Financial Strength Current
Quick Ratio 31.51
Working Capital Ratio 31.9
Leverage Ratio (MRQ) 0.08
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.27 $
Revenues (TTM) -
Cash Flow (TTM) 0.42 $
Cash 5.77 $
Book Value 2.75 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,479,068
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.